Alnylam Pharmaceuticals, Inc. (ALNY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALNY Revenue Growth
Revenue Breakdown (FY 2025)
ALNY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ALNY Revenue Analysis (2014–2025)
As of May 6, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) generated trailing twelve-month (TTM) revenue of $4.29 billion, reflecting explosive growth of +96.4% year-over-year. The most recent quarter (Q1 2026) recorded $1.17 billion in revenue, up 6.4% sequentially.
Looking at the longer-term picture, ALNY's 5-year compound annual growth rate (CAGR) stands at +49.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $3.71 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows ALNY's business is primarily driven by GIVLAARI (64%), and ONPATTRO (36%). With over half of revenue concentrated in GIVLAARI, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IONS (+47.5% YoY), ARWR (+43539.2% YoY), and BEAM (+120.0% YoY), ALNY has underperformed the peer group in terms of revenue growth. Compare ALNY vs IONS →
ALNY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALNYCurrent | $4.3B | +96.4% | +49.8% | 13.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ARWR | $829M | +43539.2% | +56.6% | 11.9% | |
 BEAM | $140M | +120.0% | +466.3% | -274.6% | |
 MRNA | $1.9B | -29.1% | +19.3% | -158.1% |
ALNY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.71B | +65.2% | $3.04B | 81.8% | $501.6M | 13.5% |
| 2024 | $2.25B | +23.0% | $1.92B | 85.6% | $-176,885,000 | -7.9% |
| 2023 | $1.83B | +76.2% | $1.52B | 83.0% | $-282,175,000 | -15.4% |
| 2022 | $1.04B | +22.9% | $868.6M | 83.7% | $-785,072,000 | -75.7% |
| 2021 | $844.3M | +71.3% | $704.1M | 83.4% | $-708,652,000 | -83.9% |
| 2020 | $492.9M | +124.3% | $414.8M | 84.2% | $-828,438,000 | -168.1% |
| 2019 | $219.8M | +193.4% | $194.7M | 88.6% | $-939,431,000 | -427.5% |
| 2018 | $74.9M | -16.7% | $73.1M | 97.6% | $-814,673,000 | -1087.6% |
| 2017 | $89.9M | +90.7% | $76.5M | 85.1% | $-500,088,000 | -556.2% |
| 2016 | $47.2M | +14.8% | $47.2M | 100.0% | $-424,587,000 | -900.3% |
Full ALNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
Is ALNY's revenue growth accelerating or slowing?
ALNY revenue is accelerating at +96.4% year-over-year, exceeding the 5-year CAGR of +49.8%. TTM revenue reached $4.3B. Growth momentum has increased versus prior periods.
What is ALNY's long-term revenue growth rate?
Alnylam Pharmaceuticals, Inc.'s 5-year revenue CAGR of +49.8% reflects the sustained expansion pattern. Current YoY growth of +96.4% is above this long-term average.
How is ALNY's revenue distributed by segment?
ALNY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.